eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) (As of 12/20/2024 03:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EFTR vs. AMPE, CMRA, CALA, ONCSQ, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, and ALVOShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech eFFECTOR Therapeutics (NASDAQ:EFTR) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Is EFTR or AMPE more profitable? Company Net Margins Return on Equity Return on Assets eFFECTOR TherapeuticsN/A N/A -146.23% Ampio Pharmaceuticals N/A N/A N/A Does the media refer more to EFTR or AMPE? In the previous week, Ampio Pharmaceuticals had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Ampio Pharmaceuticals and 0 mentions for eFFECTOR Therapeutics. eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score. Company Overall Sentiment eFFECTOR Therapeutics Neutral Ampio Pharmaceuticals Neutral Does the MarketBeat Community believe in EFTR or AMPE? eFFECTOR Therapeutics received 23 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformeFFECTOR TherapeuticsOutperform Votes2379.31% Underperform Votes620.69% Ampio PharmaceuticalsOutperform VotesNo VotesUnderperform Votes59100.00% Which has better valuation & earnings, EFTR or AMPE? Ampio Pharmaceuticals has lower revenue, but higher earnings than eFFECTOR Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeFFECTOR Therapeutics$3.55M0.00-$35.81M-$13.080.00Ampio PharmaceuticalsN/AN/A-$8.63M-$11.010.00 Do insiders & institutionals have more ownership in EFTR or AMPE? 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer EFTR or AMPE? eFFECTOR Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 11,999,900.00%. Given eFFECTOR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe eFFECTOR Therapeutics is more favorable than Ampio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eFFECTOR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, EFTR or AMPE? eFFECTOR Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 3.66, meaning that its share price is 266% more volatile than the S&P 500. SummaryeFFECTOR Therapeutics beats Ampio Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio0.0010.5989.9717.18Price / Sales0.00195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.005.094.784.78Net Income-$35.81M$151.83M$120.23M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.49%3.36%1 Year PerformanceN/A11.54%30.57%16.60% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010AMPEAmpio PharmaceuticalsN/A$0.00+420.0%N/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002CALACalithera BiosciencesN/A$0.00-92.1%N/A-99.7%$1,000.00$9.75M0.0060Analyst ForecastGap DownONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040ATNFW180 Life SciencesN/A$0.01-8.5%N/A+25.0%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/A$0.04-25.7%N/AN/A$0.00$522,000.000.00N/AGap DownAEHAWAesther Healthcare AcquisitionN/A$0.16+6.2%N/A+14.1%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.03-42.9%N/A-89.6%$0.00$40,633.000.0040News CoveragePositive NewsALVOWAlvotechN/A$2.78+1.1%N/A+26.4%$0.00$391.87M0.004Gap UpALVOAlvotech2.6628 of 5 stars$12.13+2.8%$18.00+48.4%+8.7%$0.00$93.38M0.001,026 Related Companies and Tools Related Companies Ampio Pharmaceuticals Alternatives Comera Life Sciences Alternatives Calithera Biosciences Alternatives OncoSec Medical Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Alvotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EFTR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts